Global Bleeding Disorder Treatment Market Size to Surpass USD 29.38 Billion at a CAGR of 7.3% Growth by 2032

Zion Market Research has published a new report titled “Bleeding Disorder Treatment Market By Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others), By Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic, Fibrin Sealants, and Others), and By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032”. According to the report, the global bleeding disorder treatment market size was valued at approximately USD 15.58 billion in 2023 and is predicted to reach around USD 29.38 billion by the end of 2032, expanding at a CAGR of around 7.3% from 2024 to 2032.

Browse the full “Bleeding Disorder Treatment Market By Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others), By Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic, Fibrin Sealants, and Others), and By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2024 - 2032” Report at https://www.zionmarketresearch.com/report/bleeding-disorders-treatment-market

Blood clotting is a mechanism that is activated when an injury results in bleeding inside or outside of the body. The clotting factors and certain plasma proteins are mainly responsible for the blood clotting mechanism. Blood disorders is a condition that involves malfunctioning of the clotting factors and plasma proteins, where the blood clotting mechanism either occurs slowly or doesn’t occur at all. The growing awareness about the treatment of blood disorders, improvement in the technology for treating these disorders, and growing R&D activities for the development of recombinant factors are other factors projected to drive the global bleeding disorder treatment market in the future.

The global bleeding disorder treatment market is divided on the basis of type, drug class, and region. By type, the market for bleeding disorder treatment is segmented into hemophilia B, hemophilia A, Von Willebrand disease, and others. The growing prevalence rate of hemophilia A is anticipated to fuel the hemophilia A segment in the global bleeding disorder treatment market. According to the U.S. Centers for Disease Control and Prevention, the prevalence of hemophilia A is four times higher as compared to hemophilia B.

On the basis of drug class, the bleeding disorder treatment market is sectored into plasma-derived coagulation factor concentrates, desmopressin, fibrin sealants, antifibrinolytic, recombinant coagulation factor concentrates, and others. Recombinant coagulation factor concentrates held the maximum share of the blood disorder treatment market globally in 2023, due to the lesser infection risk is related to its use. The growing research and development activities for various recombinant factors by pharmaceutical and biotechnological companies to treat blood disorders are anticipated to further fuel the growth of this segment in the future.

By region, North America is projected to dominate the global market for blood disorder treatment in the future. This can be attributed to the rising prevalence of hemophilia A, the presence of major players in the region, and the increasing population opting for prophylaxis treatment for blood diseases. Asia Pacific is expected to show the highest CAGR in the upcoming years due to the increase in awareness about blood-related disorders, the introduction of government initiatives for the treatment of blood-related disorders, and the rapidly developing healthcare infrastructure. The Middle Eastern and African region is anticipated to show a steady market growth, owing to the growing healthcare expenditure and increasing investments made by major companies.

Some key players of the global bleeding disorder treatment market are Bayer AG, CSL Behring, Novo Nordisk, Pfizer Inc., Shire PLC, Grifols SA, Octapharma, Amgen Inc., Cangene Corporation, and Alnylam Pharmaceuticals.

This report segments the global bleeding disorder treatment market as follows:

Global Bleeding Disorder Treatment Market: Type Analysis

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others

Global Bleeding Disorder Treatment Market: Drug Class Analysis

• Plasma-Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Antifibrinolytic
• Fibrin Sealants
• Others

Global Bleeding Disorder Treatment Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com